Zhenyu Li MSc , Aliya Izumi HBSc , Dominique Vervoort MD, MPH, CPH, MBA , Anika Ranadive HBSc , Subodh Verma MD , Stephen E. Fremes MD, MSc
{"title":"生物医学科学的胜率:文献计量学分析","authors":"Zhenyu Li MSc , Aliya Izumi HBSc , Dominique Vervoort MD, MPH, CPH, MBA , Anika Ranadive HBSc , Subodh Verma MD , Stephen E. Fremes MD, MSc","doi":"10.1016/j.cjco.2025.05.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The win ratio (WR), introduced in 2012, has emerged as a method to analyze hierarchical composite outcomes by prioritizing clinically significant events, unlike traditional composite time-to-event analyses, which treat events equally. However, use of the WR in biomedical research beyond cardiovascular trials remains unexplored. The study aims to investigate trends in the use of the WR in biomedical research and determine the characteristics of these articles.</div></div><div><h3>Methods</h3><div>Biomedical articles indexed in Web of Science and PubMed were retrieved for 2012-2024. Data extraction included bibliometric information and content details. Statistical analyses utilized descriptive statistics, correlation, and linear regression to assess publication trends and the distribution of WR methodologies across disciplines.</div></div><div><h3>Results</h3><div>A total of 82 studies were analyzed. Publication counts using the WR have grown significantly since its introduction, with an annual compounded growth rate of 30.2%. Most articles were randomized controlled trials (n = 68; 82.9%). Of the 68 randomized controlled trials, 46 (67.6%) were in the field of cardiology. The unmatched WR was the predominant WR approach (n = 57; 69.5%). Mortality was the highest-ranked outcome in most studies (n = 55; 67.1%), and time-to-event variables were the most frequently used across all hierarchical outcome ranks (n = 173).</div></div><div><h3>Conclusions</h3><div>The WR has gained acceptance as a robust and clinically meaningful method for analyzing composite endpoints, particularly for cardiovascular trials. Although challenges remain, its adaptability and ability to prioritize clinically relevant outcomes make it a promising tool for future biomedical research across various disciplines.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 8","pages":"Pages 1097-1107"},"PeriodicalIF":2.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Win Ratio in Biomedical Science: A Bibliometric Analysis\",\"authors\":\"Zhenyu Li MSc , Aliya Izumi HBSc , Dominique Vervoort MD, MPH, CPH, MBA , Anika Ranadive HBSc , Subodh Verma MD , Stephen E. Fremes MD, MSc\",\"doi\":\"10.1016/j.cjco.2025.05.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The win ratio (WR), introduced in 2012, has emerged as a method to analyze hierarchical composite outcomes by prioritizing clinically significant events, unlike traditional composite time-to-event analyses, which treat events equally. However, use of the WR in biomedical research beyond cardiovascular trials remains unexplored. The study aims to investigate trends in the use of the WR in biomedical research and determine the characteristics of these articles.</div></div><div><h3>Methods</h3><div>Biomedical articles indexed in Web of Science and PubMed were retrieved for 2012-2024. Data extraction included bibliometric information and content details. Statistical analyses utilized descriptive statistics, correlation, and linear regression to assess publication trends and the distribution of WR methodologies across disciplines.</div></div><div><h3>Results</h3><div>A total of 82 studies were analyzed. Publication counts using the WR have grown significantly since its introduction, with an annual compounded growth rate of 30.2%. Most articles were randomized controlled trials (n = 68; 82.9%). Of the 68 randomized controlled trials, 46 (67.6%) were in the field of cardiology. The unmatched WR was the predominant WR approach (n = 57; 69.5%). Mortality was the highest-ranked outcome in most studies (n = 55; 67.1%), and time-to-event variables were the most frequently used across all hierarchical outcome ranks (n = 173).</div></div><div><h3>Conclusions</h3><div>The WR has gained acceptance as a robust and clinically meaningful method for analyzing composite endpoints, particularly for cardiovascular trials. Although challenges remain, its adaptability and ability to prioritize clinically relevant outcomes make it a promising tool for future biomedical research across various disciplines.</div></div>\",\"PeriodicalId\":36924,\"journal\":{\"name\":\"CJC Open\",\"volume\":\"7 8\",\"pages\":\"Pages 1097-1107\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CJC Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589790X25003221\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X25003221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
win ratio (WR)于2012年引入,是一种通过优先处理临床重要事件来分析分层复合结果的方法,与传统的综合时间-事件分析不同,传统的综合时间-事件分析是平等对待事件。然而,在心血管试验以外的生物医学研究中使用WR仍未得到探索。该研究旨在调查生物医学研究中使用WR的趋势,并确定这些文章的特征。方法检索Web of Science和PubMed检索的2012-2024年生物医学文献。数据提取包括文献计量信息和内容细节。统计分析利用描述性统计、相关性和线性回归来评估出版物趋势和跨学科WR方法的分布。结果共分析了82项研究。自引入WR以来,使用WR的出版物数量显著增长,年复合增长率为30.2%。大多数文章为随机对照试验(n = 68;82.9%)。在68个随机对照试验中,46个(67.6%)在心脏病学领域。不匹配WR是主要的WR入路(n = 57;69.5%)。在大多数研究中,死亡率是排名最高的结局(n = 55;67.1%),事件发生时间变量在所有分级结果中使用频率最高(n = 173)。结论:WR作为一种可靠且具有临床意义的综合终点分析方法,已被广泛接受,特别是在心血管试验中。尽管挑战依然存在,但其适应性和优先考虑临床相关结果的能力使其成为未来跨学科生物医学研究的有希望的工具。
Win Ratio in Biomedical Science: A Bibliometric Analysis
Background
The win ratio (WR), introduced in 2012, has emerged as a method to analyze hierarchical composite outcomes by prioritizing clinically significant events, unlike traditional composite time-to-event analyses, which treat events equally. However, use of the WR in biomedical research beyond cardiovascular trials remains unexplored. The study aims to investigate trends in the use of the WR in biomedical research and determine the characteristics of these articles.
Methods
Biomedical articles indexed in Web of Science and PubMed were retrieved for 2012-2024. Data extraction included bibliometric information and content details. Statistical analyses utilized descriptive statistics, correlation, and linear regression to assess publication trends and the distribution of WR methodologies across disciplines.
Results
A total of 82 studies were analyzed. Publication counts using the WR have grown significantly since its introduction, with an annual compounded growth rate of 30.2%. Most articles were randomized controlled trials (n = 68; 82.9%). Of the 68 randomized controlled trials, 46 (67.6%) were in the field of cardiology. The unmatched WR was the predominant WR approach (n = 57; 69.5%). Mortality was the highest-ranked outcome in most studies (n = 55; 67.1%), and time-to-event variables were the most frequently used across all hierarchical outcome ranks (n = 173).
Conclusions
The WR has gained acceptance as a robust and clinically meaningful method for analyzing composite endpoints, particularly for cardiovascular trials. Although challenges remain, its adaptability and ability to prioritize clinically relevant outcomes make it a promising tool for future biomedical research across various disciplines.